炎症性肠病中的互乐金-23p19抑制剂:从目前的见解到未来的方向
Ilse A Pool1, Antonius T Otten1, Jos G W Kosterink2,3
1Department of Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands.
Journal of personalized medicine
|February 26, 2026
概括
干白素-23 (IL-23) p19 抑制剂是治疗炎症性肠病 (IBD) 的新一类药物. 这些向疗法显示出高效率和良好的安全性,精准医学指导未来使用.
科学领域:
- 胃肠道学和免疫学
- 药理学和治疗学 药理学和治疗学
背景情况:
- 介质素-23 (IL-23) 是炎症性肠病 (IBD) 中肠道炎症的关键驱动因素.
- 针对IL-23p19亚单元的单克隆抗体代表了IBD治疗的重大进展.
- 瑞桑基祖马布,米里基祖马布和古塞尔库马布是IL-23p19抑制剂的例子,其有效性已被证明.
研究的目的:
- 在IBD管理中审查目前关于IL-23p19抑制剂的知识.
- 突出类效应,临床价值和与先前治疗方法的区别.
- 概述生物标志物驱动和精确引导IL-23p19抑制剂的研究议程.
主要方法:
- 关于克罗恩病和性结肠炎的标志性第三期临床试验 (例如,SEQUENCE试验) 的审查.
- 分析IL-23p19抑制剂的疗效,安全性和使用情况.
- 讨论当前的知识差距和准确医学未来的研究方向.
主要成果:
- IL-23p19抑制剂在IBD中表现出高效和持久的反应,最近获得监管部门的批准.
- 在克罗恩氏病中,SEQUENCE试验显示了瑞桑基祖马布 (risankizumab) 与乌斯捷努马布 (ustekinumab) 的优势.
- 这些药物具有良好的安全性和方便的皮下注射.
结论:
- IL-23p19抑制剂是IBD新兴的真诚治疗类.
- 最佳的治疗定位,比较有效性和长期结果需要进一步研究.
- 精准医学方法,包括生物标志物集成,对于使用IL-23p19抑制剂进行个性化IBD治疗至关重要.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
852
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
852
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
652
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
652
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
604
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
604
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
972
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
972
Drugs for Treatment of Ulcerative Colitis in IBD
577
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
577
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
573
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
573


